Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

(2014) Gregory J Moran et al.   LANCET INFECTIOUS DISEASES

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid

(2014) Shawn Flanagan et al.   PHARMACOTHERAPY

Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)

(2013) Ronald N. Jones et al.   Brazilian Journal of Infectious Diseases

Tedizolid for the Management of Human Infections: In Vitro Characteristics

(2013) Jeffrey B. Locke et al.   CLINICAL INFECTIOUS DISEASES

Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

(2013) Philippe Prokocimer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Acute Bacterial Skin Infections: Developments Since the 2005 Infectious Diseases Society of America (IDSA) Guidelines

(2013) Gregory J. Moran et al.   JOURNAL OF EMERGENCY MEDICINE

Treatment Failure and Costs in Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study

(2013) M. J. Labreche et al.   Journal of the American Board of Family Medicine

Epidemics of Community-Associated Methicillin-Resistant Staphylococcus aureus in the United States: A Meta-Analysis

(2013) Vanja M. Dukic et al.   PLoS One

Initial Treatment Failure in Patients with Complicated Skin and Skin Structure Infections

(2013) Ariel Berger et al.   Surgical Infections

Concurrent Epidemics of Skin and Soft Tissue Infection and Bloodstream Infection Due to Community-Associated Methicillin-Resistant Staphylococcus aureus

(2012) P. Tattevin et al.   CLINICAL INFECTIOUS DISEASES

Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)

(2012) Neil Fishman et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The oxazolidinones: past, present, and future

(2011) Karen Joy Shaw et al.   Annals of the New York Academy of Sciences

Comparison of Staphylococcus aureus From Skin and Soft-Tissue Infections in US Emergency Department Patients, 2004 and 2008

(2011) D. A. Talan et al.   CLINICAL INFECTIOUS DISEASES

National epidemiology of cutaneous abscesses: 1996 to 2005

(2009) Breena R. Taira et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700)

(2009) J. B. Locke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines

(2009) S. Lemaire et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains

(2008) K. J. Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

National Trends in Ambulatory Visits and Antibiotic Prescribing for Skin and Soft-Tissue Infections

(2008) Adam L. Hersh   ARCHIVES OF INTERNAL MEDICINE